Head of Clinical Physiology for Richmond Pharmacology, Bablu Singh attended the British Cardiovascular Society (BCS) conference as a member of Faculty this month.

Future-proofing Cardiology for the next 10 years

The British Cardiovascular Society (BCS) 2023 conference returned to the Manchester Central conference centre on the 5th June. For two days, Doctors, Physiologists, Researchers and other clinicians came together to explore workforce capabilities, resilience, sustainability and multi-disciplinary working.

Upskilling the workforce

Bablu Singh, Head of Clinical Physiology at Richmond Pharmacology joined the conference as a member of Faculty, providing practical training in Adult Transthoracic Echocardiology to clinical staff attending the conference. Bablu said he was 'honoured' to have been able to support such a prestigious body that plays a pivotal role in the delivery of cardiovascular health across the UK.

London's Regional Representative

Alongside playing a key role in upskilling the workforce, Bablu was also nominated as the Regional Representative for London at the British Society of Echocardiography (BSE).The Regional Representatives are a point of contact between members and the BSE. They communicate concerns and queries from the workplace into the committees and the Advisory Council and disseminate information back into workplaces from the BSE. This can be any topic from ergonomics and staff well-being to workforce issues, etc.

The reps are also on hand to help members link up with BSE mentors and trainers within their region and organise education meetings.

For more information about Richmond Pharmacology’s expertisein Cardiology, click here.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event